Skip to main content
. Author manuscript; available in PMC: 2013 Aug 14.
Published in final edited form as: Cancer Cell. 2012 Aug 14;22(2):153–166. doi: 10.1016/j.ccr.2012.06.005

Figure 1.

Figure 1

Flow chart of methodology. (A) 15 Ph-like high-risk (HR) ALL cases were subjected to mRNA-seq, with matched normal DNA subjected to whole genome sequencing (WGS). Two cases also had WGS of tumor DNA. (B) For recurrence testing of ABL1, JAK2 and PDGFRB fusions, cases with available RNA from AALL0232 were screened by RT-PCR. The two NUP214-ABL1 cases identified in P9906 showed gain of 9q34 between NUP214 and ABL1 on SNP array analysis, and the presence of NUP214-ABL1 was confirmed by RT-PCR. Whole genome amplified (WGA) leukemic DNA was used for recurrence of IL7R and SH2B3 mutations. *FLT3 mutations were reported previously (Zhang et al., 2011). See also Figure S1.